Genix Pharmaceuticals (TSXV:GENX) Interest Expense : C$-0.14 Mil (TTM As of Jan. 2025)

View and export this data going back to 1999. Start your Free Trial

What is Genix Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Genix Pharmaceuticals's interest expense for the three months ended in Jan. 2025 was C$ -0.04 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jan. 2025 was C$-0.14 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Genix Pharmaceuticals's Operating Income for the three months ended in Jan. 2025 was C$ -0.05 Mil. Genix Pharmaceuticals's Interest Expense for the three months ended in Jan. 2025 was C$ -0.04 Mil. Genix Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Genix Pharmaceuticals Interest Expense Historical Data

The historical data trend for Genix Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genix Pharmaceuticals Interest Expense Chart

Genix Pharmaceuticals Annual Data

Trend

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Oct24

Interest Expense

Get a 7-Day Free Trial

-0.01

-0.05

-0.12

Genix Pharmaceuticals Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
Interest Expense	Get a 7-Day Free Trial															-0.02	-0.03	-0.03	-0.04	-0.04

Genix Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.14 Mil.

Genix Pharmaceuticals (TSXV:GENX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Genix Pharmaceuticals's Interest Expense for the three months ended in Jan. 2025 was C$-0.04 Mil. Its Operating Income for the three months ended in Jan. 2025 was C$-0.05 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jan. 2025 was C$0.00 Mil.

Genix Pharmaceuticals's Interest Coverage for the quarter that ended in Jan. 2025 is calculated as

Genix Pharmaceuticals did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Genix Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Genix Pharmaceuticals Corp (TSXV:GENX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

1055 West Hastings Street, Suite 300, Vancouver, BC, CAN, V6E 1J8

Website

https://www.genixpharm.com

Genix Pharmaceuticals Corp is a Canadian life sciences company focused on the research, development, manufacturing, sales, and distribution of novel, branded generic ophthalmic drugs, and ophthalmic OTC products. It operates as a formulator, manufacturer, licensor, and marketer of life sciences-related products with a focus on nutraceuticals and pharmaceuticals. Its ophthalmic products portfolio comprises different kinds of eye ointments (pending approval), and eye drops. Geographically, the company operates only in Canada.

Executives

Sina Pirooz	Director
Paul Chow	10% Security Holder, Director
Jamie A. Lewin	Director

Genix Pharmaceuticals Headlines

No Headlines